In The News Posted December 8, 2021 Share Posted December 8, 2021 - El estudio clínico de fase 3 de Henlius sobre el nuevo inhibidor de PD-1 serplulimab para el tratamiento del cáncer de pulmón de células pequeñas en estadio extenso (ES-SCLC) de primera línea cumple con el criterio de valoración principal del estudio SHANGHÁI, 8 de diciembre de 2021...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now